On September 25, 2019, Enlivex Therapeutics Ltd. announced that Dr. Schmuel Hess, Chief Executive Officer of the company delivered his notice of resignation to the Company, which resignation will become effective on December 23, 2019. Dr. Hess resigned for personal reasons. Pending selection of a new Chief Executive Officer, the Company currently intends to appoint Professor Dror Mevorach, the Company’s founder and Chief Scientific Officer, as interim Chief Executive Officer, commencing upon the effectiveness of Dr. Hess’ resignation.